Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.

A4M Medicine Redefined

Non-Profit Trusted Source of Non-Commercial Health Information

FDA Expands Dostarl...
 
Notifications
Clear all

FDA Expands Dostarlimab-gxly Approval for Endometrial Cancer

1 Posts
1 Users
0 Reactions
28 Views
Posts: 1
Guest
Topic starter
(@Dr. Healed)
New Member
Joined: 4 weeks ago

The US Food and Drug Administration (FDA) has expanded the approval of dostarlimab-gxly (Jemperli, GSK) in conjunction with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adults with primary advanced or recurrent endometrial cancer.

Prior FDA approval of the combination was granted for adults with primary advanced or recurrent endometrial cancer that was mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H).

https://www.medscape.com/viewarticle/fda-expands-dostarlimab-gxly-approval-endometrial-cancer-2024a1000eaa?form=fpf

Leave a reply

Author Name

Author Email

Title *

My Media   or drag and drop it here. Max file size 50MB
 
Preview 0 Revisions Saved